<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEVETIRACETAM</span><br/>(lev-e-tir'a-ce-tam)<br/><span class="topboxtradename">Keppra<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg, 750 mg tablets; 100 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>The precise mechanism of antiepileptic effects is unknown. It is a broad spectrum antiepileptic agent, which does not involve
         GABA inhibition.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits complex partial seizures and prevents epileptic and seizure activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for partial onset seizures in adults and children &gt;4 y of age.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to levetiracetam; labor; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; older adults; pregnancy (category C), lactation; suicidal tendencies. </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Partial Onset Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg b.i.d., may increase by 500 mg b.i.d. q2wk (max: 3000 mg/d)<br/><span class="rdage">Child (416):</span> <span class="rdroute">PO</span> 20 mg/kg/d in 2 divided doses; may increase by 20 mg/kg q2wk up to 60 mg/kg/d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 5080 mL/min: 5001000 mg q12h; 3050 mL/min: 250750 mg q12h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Reduced doses are indicated when creatinine clearance is 
         </li><li>Make dosage increment changes at 2-wk intervals.</li>
<li>Taper dose if discontinued.</li>
<li>Give supplemental doses to dialysis patients after dialysis.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Asthenia, headache, infection,</span> pain. <span class="typehead">CNS:</span>
<span class="speceff-common">Somnolence,</span> amnesia, anxiety, ataxia, depression, dizziness, emotional lability, hostility, nervousness, vertigo, paradoxical increase
      in seizures (as add-on therapy). <span class="typehead">GI:</span> Anorexia. <span class="typehead">Respiratory:</span> Cough, pharyngitis, rhinitis, sinusitis. <span class="typehead">Special Senses:</span> Diplopia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Levetiracetam does not decrease <b>estrogen, warfarin,</b> or <b>digoxin</b> levels or affect levels of other antiepileptic drugs. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and almost completely absorbed. <span class="typehead">Peak:</span> 1 h; steady-state 2 d. <span class="typehead">Distribution:</span> Metabolism: Minimal hepatic metabolism. <span class="typehead">Elimination:</span> Renally eliminated. <span class="typehead">Half-Life:</span> 7.1 h (9.6 h in older adults). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor &amp; notify physician of difficulty with gait or coordination.</li>
<li>Lab tests: Periodic CBC with differential, Hct &amp; Hgb, LFTs.</li>
<li>Monitor for changes in phenytoin blood levels with coadministered drugs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not abruptly discontinue drug. MUST use gradual dose reduction/taper.</li>
<li>Notify physician of intention to become pregnant.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>